[go: up one dir, main page]

MX2013007622A - Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson. - Google Patents

Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson.

Info

Publication number
MX2013007622A
MX2013007622A MX2013007622A MX2013007622A MX2013007622A MX 2013007622 A MX2013007622 A MX 2013007622A MX 2013007622 A MX2013007622 A MX 2013007622A MX 2013007622 A MX2013007622 A MX 2013007622A MX 2013007622 A MX2013007622 A MX 2013007622A
Authority
MX
Mexico
Prior art keywords
opioid
parkinson
disease
treatment
combination
Prior art date
Application number
MX2013007622A
Other languages
English (en)
Other versions
MX354125B (es
Inventor
Michael Hopp
Claudia Trenkwalder
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43903970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013007622(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of MX2013007622A publication Critical patent/MX2013007622A/es
Publication of MX354125B publication Critical patent/MX354125B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona una forma de dosificación farmacéutica que comprende un agonista opioide y un antagonista opioide para su uso en el tratamiento de la enfermedad de Parkinson. La presente invención también se refiere al uso de un agonista opioide y un antagonista opioide en dicha forma de dosificación.
MX2013007622A 2010-12-28 2011-12-27 Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson. MX354125B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10197210 2010-12-28
PCT/EP2011/074103 WO2012089738A1 (en) 2010-12-28 2011-12-27 A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease

Publications (2)

Publication Number Publication Date
MX2013007622A true MX2013007622A (es) 2013-12-06
MX354125B MX354125B (es) 2018-02-14

Family

ID=43903970

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007622A MX354125B (es) 2010-12-28 2011-12-27 Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson.

Country Status (20)

Country Link
US (1) US20140037729A1 (es)
EP (1) EP2658523A1 (es)
JP (2) JP5864606B2 (es)
KR (2) KR101618929B1 (es)
CN (1) CN103347495B (es)
AR (1) AR084620A1 (es)
AU (1) AU2011351447B2 (es)
BR (1) BR112013016862A2 (es)
CA (1) CA2822528C (es)
CL (1) CL2013001943A1 (es)
EA (1) EA025747B1 (es)
MX (1) MX354125B (es)
MY (1) MY162895A (es)
NZ (1) NZ612837A (es)
PH (1) PH12013501244A1 (es)
SG (1) SG191208A1 (es)
TW (2) TWI554271B (es)
UA (1) UA109301C2 (es)
WO (1) WO2012089738A1 (es)
ZA (1) ZA201304303B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012028656A2 (pt) 2010-05-10 2016-08-09 Euro Celtique Sa combinação de grânulos carregados ativos com ativos adicionais
EP2568968B1 (en) 2010-05-10 2017-07-12 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
JP5864606B2 (ja) * 2010-12-28 2016-02-17 ユーロ−セルティーク エス．エイ． パーキンソン病の治療におけるオピオイド作動薬とオピオイド拮抗薬との組合せ
US9918980B2 (en) 2011-04-29 2018-03-20 Rutgers, The State University Of New Jersey Method of treating dyskinesia
US10736889B2 (en) 2011-04-29 2020-08-11 Rutgers, The State University Of New Jersey Method of treating dyskinesia
PL2701707T3 (pl) * 2011-04-29 2021-03-08 Rutgers, The State University Of New Jersey Sposób leczenia dyskinezji
US10071088B2 (en) 2012-06-26 2018-09-11 Precondit, Llc Anti-nausea drug combinations
KR20160034352A (ko) * 2013-07-23 2016-03-29 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
US9814710B2 (en) 2013-11-13 2017-11-14 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
CA2847781C (en) * 2014-03-28 2019-03-12 Purdue Pharma Reducing drug liking in a subject
US20150352099A1 (en) * 2014-06-04 2015-12-10 Mentinova Inc. Compositions and Methods of Reducing Sedation
EP3183232B1 (en) 2014-08-22 2023-05-03 The Arizona Board of Regents on behalf of The University of Arizona Substituted 1-arylethyl-4-acylaminopiperidine derivatives as opioid/alpha-adrenoreceptor modulators and method of their preparation
WO2016116615A1 (en) * 2015-01-23 2016-07-28 Euro-Celtique S.A. A combination of hydromorphone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US20160256451A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Dosage of naloxone
ES2869981T3 (es) * 2015-05-26 2021-10-26 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Composiciones para su uso en el tratamiento de la enfermedad de parkinson y trastornos relacionados
US20180104236A1 (en) * 2016-09-26 2018-04-19 Euro-Celtique S. A. Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio
CN114828961B (zh) 2019-08-11 2024-03-29 卡帕制药有限责任公司 通过阿片类己二烯酸酯和任选取代的己二烯酸酯增强阿片受体结合的组合物及方法
WO2021087456A1 (en) * 2019-10-31 2021-05-06 Fung Constance H Methods, systems, and apparatus for tapering or uptitrating drug dosages

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
NZ520554A (en) * 2000-02-08 2005-08-26 Euro Celtique S Tamper-resistant oral opioid agonist formulations
AU782523B2 (en) * 2000-07-13 2005-08-04 Euro-Celtique S.A. Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics
PT1416842E (pt) * 2001-07-18 2009-03-31 Euro Celtique Sa Composições farmacêuticas de oxicodona e naloxona
US20060177381A1 (en) * 2002-02-15 2006-08-10 Howard Brooks-Korn Opiopathies
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
US20070232638A1 (en) * 2006-04-03 2007-10-04 Howard Brooks-Korn Opiopathies
WO2009132313A2 (en) * 2008-04-25 2009-10-29 Progenics Pharmaceuticals, Inc. Morphinan derivatives of organic and inorganic acids
RU2478388C2 (ru) * 2008-07-07 2013-04-10 Еуро-Селтик С.А. Фармацевтическая композиция, содержащая опиоидный антагонист, для лечения задержки мочи
RU2522212C2 (ru) * 2009-03-10 2014-07-10 Еуро-Селтик С.А. Фармацевтические композиции с мгновенным высвобождением, содержащие оксикодон и налоксон
GB0909680D0 (en) * 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
JP5864606B2 (ja) * 2010-12-28 2016-02-17 ユーロ−セルティーク エス．エイ． パーキンソン病の治療におけるオピオイド作動薬とオピオイド拮抗薬との組合せ

Also Published As

Publication number Publication date
CN103347495B (zh) 2017-06-20
UA109301C2 (uk) 2015-08-10
CN103347495A (zh) 2013-10-09
KR101618929B1 (ko) 2016-05-09
JP2016040268A (ja) 2016-03-24
TW201302199A (zh) 2013-01-16
JP5864606B2 (ja) 2016-02-17
JP2014501268A (ja) 2014-01-20
CA2822528A1 (en) 2012-07-05
US20140037729A1 (en) 2014-02-06
AU2011351447B2 (en) 2016-02-25
EA025747B1 (ru) 2017-01-30
TWI554271B (zh) 2016-10-21
TW201628618A (zh) 2016-08-16
EA201390977A1 (ru) 2013-12-30
EP2658523A1 (en) 2013-11-06
CA2822528C (en) 2017-07-18
NZ612837A (en) 2014-11-28
SG191208A1 (en) 2013-07-31
KR20130106431A (ko) 2013-09-27
CL2013001943A1 (es) 2013-11-29
KR20150076262A (ko) 2015-07-06
PH12013501244A1 (en) 2013-07-15
AU2011351447A1 (en) 2013-07-25
MX354125B (es) 2018-02-14
JP6074003B2 (ja) 2017-02-01
BR112013016862A2 (pt) 2016-10-04
ZA201304303B (en) 2014-02-26
KR101632858B1 (ko) 2016-06-22
AR084620A1 (es) 2013-05-29
MY162895A (en) 2017-07-31
WO2012089738A1 (en) 2012-07-05

Similar Documents

Publication Publication Date Title
MX2013007622A (es) Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson.
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
SV2009003098A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
PE20141171A1 (es) Forma de dosificacion farmaceutica oral resistente a alteracion comprendiendo agonista opioide y antagonista opioide
CL2012000702A1 (es) Uso de un agonista del receptor de acetilcolina nicotinico alfa-7 para el tratamiento de la discinesia asociada a la terapia con agonista de dopamina en la enfermedad de parkinson.
CL2014001450A1 (es) Forma de dosis de liberacion controlada solida que comprende un analgesico opioide dispersado en un material de matriz; metodo de preparacion; uso en el tratamiento del dolor.
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
EA201390804A1 (ru) Лекарственная форма лакозамида для приема один раз в сутки
CL2008000418A1 (es) Uso de un antagonista de la il-23 para el tratamiento de una infeccion fungica.
ES2542042R1 (es) Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
MX348933B (es) Composiciones, formas de dosificacion y coadministracion de un compuesto agonista opioide y un compuesto analgesico.
UY31922A (es) Compuestos
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
EA202091356A1 (ru) A2a АНТАГОНИСТЫ КАК УСИЛИТЕЛИ КОГНИТИВНОЙ И МОТОРНОЙ ФУНКЦИЙ
SG11201601306QA (en) An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease
IT1406068B1 (it) Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
DOP2010000361A (es) Dronedarona para la prevencion de la cardioversion
CL2013000335A1 (es) Forma altamente cristalina de valsartan; proceso para prepararla; composicion farmaceutica que la comprende y uso en el tratamiento de la hipertension.
ECSP12011951A (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.
BR112013024196A2 (pt) complexos de gálio, composições farmacêuticas e métodos de uso

Legal Events

Date Code Title Description
FG Grant or registration